APGN — Apexigen Income Statement
0.000.00%
HealthcareSpeculativeMicro Cap
- $12.20m
- $2.83m
Annual income statement for Apexigen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Total Revenue | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Total Operating Expenses | 24.5 | 29 | 32.7 |
Operating Profit | -24.5 | -29 | -32.7 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -24.1 | -28.9 | -32.1 |
Net Income After Taxes | -24.1 | -28.9 | -32.1 |
Net Income Before Extraordinary Items | |||
Net Income | -24.1 | -28.9 | -32.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -24.1 | -28.9 | -32.1 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -1.12 | -1.35 | -1.42 |
Dividends per Share |